Source: ERJ Open Res, 4 (1) 00058-2017; 10.1183/23120541.00058-2017
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jacques Cadranel, Alexis B. Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse. Real-life experience of ceritinib in crizotinib-pretreated ALK⁺ advanced non-small cell lung cancer patients. ERJ Open Res, 4 (1) 00058-2017; 10.1183/23120541.00058-2017

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic management of ALK+ nonsmall cell lung cancer patients Source: Eur Respir J 2015; 46: 230-242 Year: 2015 Advanced non-small cell lung cancer in elderly patients Source: Breathe 2012; 9: 26-34 Year: 2012 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Do cavitating non-small cell lung cancer patients have a more aggressive disease? Source: Eur Respir J 2006; 28: Suppl. 50, 84s Year: 2006 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Salvage surgery in patients with locally advanced non-small cell lung cancer – outcomes and longtime results Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 A rare choroidal metastasis in ALK+ non-small cell lung cancer (NSCLC) that responds to Crizotinib Source: International Congress 2019 – CCC Thoracic oncology Year: 2019 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 How to handle oligometastatic disease in nonsmall cell lung cancer Source: Eur Respir Rev, 30 (159) 200234; 10.1183/16000617.0234-2020 Year: 2021 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Management of brain metastases in patients with non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009